As shown in Table 1, when considering variants individually, three variants had posterior probabilities >0.99 that categorized them as pathogenic (class 5) providing convincing evidence that these variants are associated with a cancer risk equivalent to the average (mostly truncating) pathogenic variants in BRCA2. For all variants combined, the likelihood ratio in favour of causality was 4.39*1025, and the posterior probability of pathogenicity was 1.00. This evidence concerns the gene BRCA2 and cancer.